Building on previous cardiovascular outcome trials with glucagon-like peptide 1 receptor agonists, the AMPLITUDE-O trial reported significant improvements in major adverse cardiovascular and kidney outcomes with efpeglenatide in type 2 diabetes. A longer-term trial with dose-dependent analysis on kidney outcome components will better define the effects of efpeglenatide in the diabetic kidney.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F. & Saraiva, J. F. K. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovas. Diabetol. 17, 157 (2018).
Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108269 (2021).
Zelniker, T. A. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139, 2022–2031 (2019).
Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018).
Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).
Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).
Bentley-Lewis, R. et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am. Heart J. 169, 631–638 (2015).
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
van der Aart-van der Beek, A. B. et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes. Metab. 22, 2493–2498 (2020).
Bethel, M. A. et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes https://doi.org/10.2337/db18-522-P (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.E.C. has previously reviewed grants and has been a member of honorary advisory boards for companies that manufacture GLP1 agonists and other glucose-lowering drugs, including AstraZeneca, Novo Nordisk, Boehringer Ingelheim, MSD, Novartis, Sanofi and Eli Lilly and Company. J.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Ma, J., Cooper, M.E. Potential cardiorenal benefits of efpeglenatide in diabetes. Nat Rev Nephrol 17, 708–709 (2021). https://doi.org/10.1038/s41581-021-00475-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-021-00475-7